Abstract

Infection with Leishmania amazonensis and other members of the Leishmania mexicana complex can lead to diverse clinical manifestations, some of which are relatively difficult to control, even with standard chemotherapy. Diffuse cutaneous leishmaniasis (CL) is a rare but severe form, and its clinical hallmark is excessive parasitic growth in infected cells accompanied by profound impairments in host immune responses to the parasites. Since these parasites also cause non-healing CL in most inbred strains of mice, these animals are valuable models for dissecting the mechanisms of persistent infection and disease pathogenesis. In comparison to other Leishmania species, L. amazonensis infections are most remarkable for their ability to repress the activation and effector functions of macrophages, dendritic cells, and CD4+ T cells, implying discrete mechanisms at work. In addition to this multilateral suppression of host innate and adaptive immunity, the activation of types I and II interferon-mediated responses and autophagic/lipid metabolic pathways actually promotes rather than restrains L. amazonensis infection. These seemingly contradictory findings reflect the remarkable adaptation of the parasites to the ancient defense machinery of the host, as well as the complex parasite–host interactions at different stages of infection, which collectively contribute to non-healing leishmaniasis in the New World. This review article highlights new evidence that reveals the strategies utilized by L. amazonensis parasites to subvert or modulate host innate defense machinery in neutrophils and macrophages, as well as the regulatory roles of host innate responses in promoting parasite survival and replication within the huge parasitophorous vacuoles. A better understanding of unique features in host responses to these parasites at early and late stages of infection is important for the rational design of control strategies for non-healing leishmaniasis.

Highlights

  • Leishmania amazonensis is a member of the Leishmania mexicana complex and the etiological agent for a broad-spectrum of leishmaniasis in South American countries

  • In patients with Leishmania tropica and Leishmania major infections in India and Africa, diffuse CL (DCL) is considered a clinical indicator of HIV co-infection (Niamba et al, 2007; Khandelwal et al, 2011)

  • A detrimental regulatory loop at very early stages of the infection with L. amazonensis can lead to the activation and expansion of pathogenic CD4+ T and B cells and non-healing lesions

Read more

Summary

Introduction

Leishmania amazonensis is a member of the Leishmania mexicana complex and the etiological agent for a broad-spectrum of leishmaniasis in South American countries. It can cause mild cutaneous leishmaniasis (CL), diffuse CL (DCL), and deadly visceral leishmaniasis (Silveira et al, 2004). Patients with DCL share some clinical characteristics. They have defective responses for the leishmanin skin test and poor antigen-stimulated T cell proliferation in vitro, some patients remain responsiveness to other antigens such as Abbreviations: Atg, autophagy-related genes; CL, cutaneous leishmaniasis; DCL, diffuse cutaneous leishmaniasis; IFNAR, type I interferon-α receptor; ISCL, inositol phosphosphingolipid phospholipase C-like; LYST/Beige, lysosomal trafficking regulator gene; PKR, dsRNA-dependent protein kinase; PS, phosphatidylserine; PV, parasitophorous vacuoles; SOD1, superoxide dismutase 1; TCR, T cell receptor

Objectives
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call